文献速递头颈外科

经新辅助化疗与经口机器人手术后避免辅助放疗在特定HPV阳性口咽癌中的效果

Adjuvant Radiation Sparing after Neoadjuvant Chemotherapy and TORS in Selected HPV-Positive Oropharyngeal Cancer.
PubMed 文献 · Laryngoscope · 2024-12-05

回顾性队列纳入84例接受新辅助化疗后经口机器人手术且未行辅助放疗的HPV阳性口咽鳞状细胞癌患者,无患者死亡;1、2、3年无病生存率分别为92.8%、87.0%、84.4%,局部、区域、远处复发率分别为7.0%、9.5%、3.6%,挽救治疗挽救率100%;肿瘤复发预测因素包括阳性淋巴结数目(风险比2.66)和诊断时临床III期(风险比7.65)。

要点

  • 1、2、3年无病生存率(95%CI)分别为92.8%(87.4-98.5)、87.0%(79.7-94.9)、84.4%(76.0-93.8)。
  • 局部、区域、远处复发率分别为7.0%、9.5%、3.6%,挽救治疗挽救率100%。
  • 肿瘤复发预测因素包括阳性淋巴结数目(风险比2.66;95%CI 1.19-5.92)和诊断时临床III期(风险比7.65;95%CI 1.97-29.7)。

核心结论

  • 基于病理不良特征推荐辅助治疗似乎与特定HPV阳性口咽鳞状细胞癌患者接受新辅助化疗和经口机器人手术后获得良好结局相关。
  • 未来研究应聚焦于完善推荐辅助放疗的标准,以进一步降低复发率并减少治疗相关毒性,助力HPV相关口咽鳞状细胞癌的个体化治疗策略。

研究设计与样本

  • 回顾性队列研究,连续纳入84例接受新辅助化疗后经口机器人手术且未行辅助放疗的HPV阳性口咽鳞状细胞癌患者。
  • 主要结局为无病生存率,同时评估复发模式(局部、区域、远处)、挽救治疗结局和肿瘤复发预测因素。

主要发现

  • 研究期间无患者死亡。
  • 1、2、3年无病生存率(95%CI)分别为92.8%(87.4-98.5)、87.0%(79.7-94.9)、84.4%(76.0-93.8)。
  • 局部、区域、远处复发率分别为7.0%、9.5%、3.6%。
  • 挽救治疗挽救率为100%。
  • 肿瘤复发预测因素包括阳性淋巴结数目(风险比2.66;95%CI 1.19-5.92)和诊断时临床III期(风险比7.65;95%CI 1.97-29.7)。

临床怎么用

  • 作者认为,基于病理不良特征推荐辅助治疗似乎与特定HPV阳性口咽鳞状细胞癌患者接受新辅助化疗和经口机器人手术后获得良好结局相关。
  • 作者建议未来研究应聚焦于完善推荐辅助放疗的标准,以进一步降低复发率并减少治疗相关毒性,助力个体化治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Transoral robotic surgery (TORS) has shown promising results in treating human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), and there has been increasing interest in incorporating neoadjuvant chemotherapy (NCT) prior to TORS. This study aimed to assess the feasibility and safety of sparing adjuvant RT following NCT and TORS. METHODS: A retrospective cohort study included consecutive patients with HPV-positive OPSCC who underwent NCT followed by TORS without adjuvant RT. Disease-free survival (DFS) was the primary outcome. Pattern of recurrence (local, regional, and distant), salvage treatment outcomes, and predictors of tumor recurrence were also assessed. RESULTS: A total of 84 patients were included in the analysis. No patients died during the study period. DFS rates (95% Confidence Interval, CI) at 1, 2, and 3 years were 92.8% (87.4-98.5), 87.0% (79.7-94.9), and 84.4% (76.0-93.8), respectively. Local, regional, and distant recurrence rates were 7.0%, 9.5%, and 3.6%, respectively. Salvage treatment achieved a 100% salvage rate. Predictors of tumor recurrence included the number of positive lymph nodes (hazard ratio: 2.66; 95% CI: 1.19-5.92) and clinical stage III at diagnosis (hazard ratio: 7.65; 95% CI: 1.97-29.7). CONCLUSIONS: Recommendation of adjuvant treatment based on pathologic adverse features appears to be associated with favorable outcomes in selected HPV-positive OPSCC cases treated with NCT and TORS. Future studies should focus on refining criteria for recommending adjuvant RT to further reduce recurrence rates and minimize treatment-related toxicity, contributing to personalized treatment strategies for HPV-related OPSCC. LEVEL OF EVIDENCE: 4 Laryngoscope, 135:1401-1408, 2025.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Costantino A, Sampieri C, Sim NS, et al. Adjuvant Radiation Sparing after Neoadjuvant Chemotherapy and TORS in Selected HPV-Positive Oropharyngeal Cancer. Laryngoscope. 2024. PMID: 39632778. doi:10.1002/lary.31940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。